@prefix ns1: <http://linked.opendata.cz/ontology/drug-encyclopedia/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<http://linked.opendata.cz/resource/ATC/N04BA02> a ns1:ATCConcept ;
    skos:notation "N04BA02" ;
    skos:prefLabel "Levodopa a inhibitor dekarboxylázy"@cs,
        "Levodopa and decarboxylase inhibitor"@en .

<http://linked.opendata.cz/resource/ATC/N04BA03> a ns1:ATCConcept ;
    skos:notation "N04BA03" ;
    skos:prefLabel "Levodopa, inhibitor dekarboxylázy a inhibitor COMT"@cs,
        "LEVODOPA, DECARBOXYLASE INHIBITOR AND COMT INH."@en .

<http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0003345> a ns1:Ingredient ;
    ns1:contraindicatedWith <http://linked.opendata.cz/resource/ndfrt/disease/N0000000999>,
        <http://linked.opendata.cz/resource/ndfrt/disease/N0000001969>,
        <http://linked.opendata.cz/resource/ndfrt/disease/N0000003321> ;
    ns1:description "An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.     "@en ;
    ns1:hasMechanismOfAction <http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000133>,
        <http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000203> ;
    ns1:hasMedicinalProduct <http://linked.opendata.cz/resource/sukl/medicinal-product/DUODOPA>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-100-MG-25-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-125-MG-31-25-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-150-MG-37-5-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-200-MG-50-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-50-MG-12-5-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-75-MG-18-75-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-100-MG-25-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-125-MG-31-25-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-150-MG-37-5-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-175-MG-43-75-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-200-MG-50-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-50-MG-12-5-MG-200-MG>,
        <http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-75-MG-18-75-MG-200-MG> ;
    ns1:hasPharmacologicalAction <http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001494>,
        <http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0007520>,
        <http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0023499> ;
    ns1:hasPhysiologicEffect <http://linked.opendata.cz/resource/ndfrt/physiologic-effect/N0000009183> ;
    ns1:hasPregnancyCategory <http://linked.opendata.cz/resource/fda-spl/pregnancy-category/C> ;
    ns1:mayTreat <http://linked.opendata.cz/resource/ndfrt/disease/N0000002327> ;
    ns1:title "Karbidopa"@cs,
        "Carbidopa"@en .

<http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001494> a ns1:PharmacologicalAction ;
    ns1:description "Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.     "@en ;
    ns1:title "Antiparkinsonika"@cs,
        "Antiparkinson agents"@en .

<http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0007520> a ns1:PharmacologicalAction ;
    ns1:description "Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.     "@en ;
    ns1:title "Enzymy - inhibitory"@cs,
        "Enzyme inhibitors"@en .

<http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0023499> a ns1:PharmacologicalAction ;
    ns1:description "Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.     "@en ;
    ns1:title "Dopaminové látky"@cs,
        "Dopamine agents"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000000999> a ns1:DiseaseOrFinding ;
    ns1:description "Immunologically mediated adverse reactions to medicinal substances used legally or illegally.     "@en ;
    ns1:title "Léková alergie"@cs,
        "Drug hypersensitivity"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000001969> a ns1:DiseaseOrFinding ;
    ns1:description "A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)     "@en ;
    ns1:title "Melanom"@cs,
        "Melanoma"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000002327> a ns1:DiseaseOrFinding ;
    ns1:description "A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)     "@en ;
    ns1:title "Parkinsonova nemoc"@cs,
        "Parkinson disease"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000003321> a ns1:DiseaseOrFinding ;
    ns1:description "A form of glaucoma in which the intraocular pressure increases because the angle of the anterior chamber is blocked and the aqueous humor cannot drain from the anterior chamber.     "@en ;
    ns1:title "Glaukom s uzavřeným úhlem"@cs,
        "Glaucoma, angle-closure"@en .

<http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000133> a ns1:MechanismOfAction ;
    ns1:title "Enzyme Inhibitors"@en .

<http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000203> a ns1:MechanismOfAction ;
    ns1:title "Dopamine Receptor Interactions"@en .

<http://linked.opendata.cz/resource/ndfrt/physiologic-effect/N0000009183> a ns1:PhysiologicEffect ;
    ns1:title "Increased Central Nervous System Dopamine Activity"@en .

<http://linked.opendata.cz/resource/sukl/medicinal-product/DUODOPA> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA02> ;
    ns1:title "DUODOPA"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-100-MG-25-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "LEVODOPA/CARBIDOPA/ENTACAPONE ORION 100 MG/25 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-125-MG-31-25-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "LEVODOPA/CARBIDOPA/ENTACAPONE ORION 125 MG/31,25 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-150-MG-37-5-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "LEVODOPA/CARBIDOPA/ENTACAPONE ORION 150 MG/37,5 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-200-MG-50-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "LEVODOPA/CARBIDOPA/ENTACAPONE ORION 200 MG/50 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-50-MG-12-5-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "LEVODOPA/CARBIDOPA/ENTACAPONE ORION 50 MG/12,5 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/LEVODOPA-CARBIDOPA-ENTACAPONE-ORION-75-MG-18-75-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "LEVODOPA/CARBIDOPA/ENTACAPONE ORION 75 MG/18,75 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-100-MG-25-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "STALEVO 100 MG/25 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-125-MG-31-25-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "STALEVO 125 MG/31,25 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-150-MG-37-5-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "STALEVO 150 MG/37,5 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-175-MG-43-75-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "STALEVO 175 MG/43,75 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-200-MG-50-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "STALEVO 200 MG/50 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-50-MG-12-5-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "STALEVO 50 MG/12,5 MG/200 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/STALEVO-75-MG-18-75-MG-200-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept <http://linked.opendata.cz/resource/ATC/N04BA03> ;
    ns1:title "STALEVO 75 MG/18,75 MG/200 MG"@cs .


